Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,892 shares of the company’s stock after selling 1,009 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of Castle Biosciences worth $1,063,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CSTL. Point72 Asset Management L.P. lifted its holdings in Castle Biosciences by 828.3% in the third quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company’s stock valued at $14,237,000 after acquiring an additional 445,415 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Castle Biosciences by 147.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock worth $4,719,000 after buying an additional 98,571 shares during the period. State Street Corp raised its stake in shares of Castle Biosciences by 9.8% during the 3rd quarter. State Street Corp now owns 680,001 shares of the company’s stock worth $19,394,000 after buying an additional 60,924 shares during the period. Lisanti Capital Growth LLC raised its stake in shares of Castle Biosciences by 60.2% during the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock worth $4,412,000 after buying an additional 58,160 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of Castle Biosciences during the 3rd quarter worth approximately $1,478,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Stock Down 4.1 %

NASDAQ CSTL opened at $21.32 on Thursday. The business has a fifty day moving average price of $26.87 and a 200 day moving average price of $29.05. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The company has a market cap of $597.11 million, a P/E ratio of 106.61 and a beta of 0.98.

Analyst Ratings Changes

Several research analysts have recently weighed in on CSTL shares. Scotiabank upped their target price on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Robert W. Baird upped their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences presently has a consensus rating of “Buy” and a consensus target price of $40.00.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 9,364 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total value of $265,375.76. Following the completion of the sale, the insider now directly owns 84,762 shares in the company, valued at $2,402,155.08. This represents a 9.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,799 shares of company stock valued at $824,289. 7.20% of the stock is owned by insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.